15.09.2024, 719 Zeichen
Valneva: Valneva, an Austrian/French specialty vaccine company, issued 23 million new ordinary shares at a price of €2.66 per Offer Share to certain categories of investors via a private placement through an accelerated bookbuilding process starting immediately. The company intends to use the net proceeds of the Private Placement primarily to fund the continuing development of the Company’s clinical programs which include notably the Phase 3 pediatric and Phase 4 programs for the chikungunya vaccine as well as the anticipated Phase 2 programs for the Shigella and Zika vaccine candidates.
Valneva: weekly performance:
(From the 21st Austria weekly https://www.boerse-social.com/21staustria (13/09/2024)
SportWoche Podcast #140: Flag Football und Österreichs Top-Position dabei, erklärt von Ines-Jeanne Paupie
1.
Valneva - Key Upcoming Catalysts and Newsflow
>> Öffnen auf photaq.com
Aktien auf dem Radar:Pierer Mobility, UBM, Palfinger, Immofinanz, Addiko Bank, CA Immo, SBO, Porr, Rosenbauer, EuroTeleSites AG, Frequentis, Kostad, Linz Textil Holding, Marinomed Biotech, Wiener Privatbank, Warimpex, Agrana, Amag, EVN, Flughafen Wien, OMV, Österreichische Post, Telekom Austria, Uniqa, VIG, E.ON , BASF, Zalando, Mercedes-Benz Group, Allianz, Hannover Rück.
Marinomed
Erforscht und entwickelt völlig neuartige Technologieplattformen, die innovative Therapien gegen Atemwegs- und Augenerkrankungen ermöglichen. Aus wissenschaftlichen Ideen werden so neue Patente, Marken und Produkte geschaffen.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner